MARKET

HROW

HROW

Harrow Health Inc
NASDAQ
29.03
-9.01
-23.69%
After Hours: 29.46 +0.43 +1.48% 16:35 05/12 EDT
OPEN
33.87
PREV CLOSE
38.04
HIGH
33.87
LOW
28.82
VOLUME
5.40M
TURNOVER
--
52 WEEK HIGH
54.85
52 WEEK LOW
24.50
MARKET CAP
1.08B
P/E (TTM)
-207.6538
1D
5D
1M
3M
1Y
5Y
1D
Harrow projects $71M-$81M Q2 revenue while reaffirming $350M-$365M 2026 outlook
Seeking Alpha · 2h ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 3h ago
Harrow Stock Tumbles on Weaker 1Q Revenue, Wider Loss
Dow Jones · 4h ago
Transcript: Harrow Q1 2026 Earnings Conference Call
Benzinga · 5h ago
AST SpaceMobile Posts Downbeat Q1 Results, Joins Hims & Hers Health, Gitlab And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 8h ago
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Hims & Hers Health (HIMS) and ArriVent BioPharma, Inc. (AVBP)
TipRanks · 8h ago
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Benzinga · 10h ago
Closing Bell Movers: Hims & Hers down 12% on earnings miss
TipRanks · 20h ago
More
About HROW
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

Webull offers Harrow Inc stock information, including NASDAQ: HROW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HROW stock methods without spending real money on the virtual paper trading platform.